Biotech in 2019: Gene Therapies, Cancer Immunotherapies, and mRNA
2018 has not been kind to many expensive stocks — that is, to those that trade at elevated price-to-earnings ratios. The technology giants were the last to fall as the rolling correction finally reached them in October, and fall they did, with the Nasdaq 100 index down 16.3% between October Read more…